Background: Abstinence and no heavy drinking days are currently the only Food and Drug Administration-approved end points in clinical trials for alcohol use disorder (AUD). Many individuals who fail to meet these criteria may substantially reduce their drinking during treatment, and most individuals with AUD prefer drinking reduction goals. One-and two-level reductions in World Health Organization (WHO) drinking risk levels have been proposed as alternative end points that reflect reduced drinking and are associated with reductions in drinking consequences, improvements in mental health, and reduced risk of developing alcohol dependence. The current study examined the association between WHO drinking risk level reductions and improvements in physical health and quality of life in a sample of individuals with alcohol dependence.
XCESSIVE ALCOHOL CONSUMPTION is associated with significant morbidity and all-cause mortality (GBD 2016 Alcohol Collaborators, 2018 Rehm et al., 2003 Rehm et al., , 2014 Shield et al., 2013) and is one of the leading causes of preventable death worldwide (Whiteford et al., 2013; World Health Organization [WHO], 2011) . Evidence of a curvilinear relationship exists between increased alcohol consumption and risk of cardiovascular disease (Wood et al., 2018) , with 50% of heavy drinkers estimated to have elevated blood pressure (Estruch et al., 2005) . Most of the studies examining the association between alcohol use and morbidity and mortality have focused on population-based samples, which tend to have lower average alcohol intake than clinical samples of individuals with alcohol use disorder (AUD). Importantly, those with AUD who continue to drink heavily have the greatest mortality risk, whereas those who reduce their alcohol consumption have significantly lower mortality risk and estimated disease burden (Franc ßois et al., 2014) , even among those who do not achieve abstinence.
Abstinence has long been considered the goal of AUD treatment (Betty Ford Institute Consensus Panel, 2007; Mann et al., 2017) . However, multiple studies have shown that reductions in alcohol consumption during treatment are associated with significant improvements in physical health, as reflected by reductions in blood pressure (Baros et al., 2008; Stewart et al., 2008) and improvements in liver tests and quality of life (LoCastro et al., 2009) . Further, individuals with AUD who achieve low-risk drinking (typically defined as not exceeding 3 drinks for women and 4 drinks for men on a drinking day) have been shown to be similar to abstainers on a variety of physical and mental health outcomes (Kline-Simon et al., 2017; Maisto et al., 2010; Witkiewitz, 2013; Witkiewitz et al., 2017b) , as well as on healthcare costs (Aldridge et al., 2016; Kline-Simon et al., 2014) . Some individuals in AUD treatment who exceed the low-risk drinking cutoffs have improved post treatment social functioning and quality of life, and reduced mental health symptoms and alcohol-related problems, similar to those of abstainers and low-risk drinkers (Wilson et al., 2016; Witkiewitz et al., 2018) . These findings are particularly important in light of the fact that most individuals who seek treatment (especially those in clinical trials and those presenting to other medical settings, such as primary care) are interested primarily in nonabstinent drinking reduction goals (DeMartini et al., 2014) . Moreover, many individuals with AUD report not seeking treatment because they do not want to abstain from alcohol (Center for Behavioral Health Statistics and Quality, 2017) . Extending treatment options to target reductions in drinking, rather than complete abstinence, could expand the reach of alcohol treatment and have an important impact on public health Maremmani et al., 2015; van Amsterdam and van den Brink, 2013) .
End Point Definitions in Alcohol Clinical Trials
Abstinence is one of the primary end points (i.e., treatment outcomes) that is currently accepted by the Food and Drug Administration (FDA) for Phase III clinical trials (FDA, 2015) . The FDA also accepts no heavy drinking days (defined as more than 3 drinks for women and more than 4 drinks for men in a day) as a primary end point. Both abstinence and no heavy drinking days are considered surrogate end points that are "reasonably predictive of clinical benefit (e.g., improvement in the way the patient feels or functions)" (FDA, 2015, p. 2) . Meanwhile, the European Medicines Agency (EMA; 2010) not only accepts abstinence as a primary end point for Phase III alcohol clinical trials, but also accepts intermediate harm reduction end points, including reductions in total alcohol consumption, heavy drinking days, or in the WHO (2000) drinking risk levels, which are defined by sex-specific limits for grams of alcohol consumed per day (Fig. 1) . Similar to the FDA guidance, the EMA guidance notes that intermediate harm reduction end points should be evaluated in terms of significantly "improved health outcome on an individual patient level" (EMA, 2010, p. 10) .
WHO Drinking Risk Levels as a Drinking Reduction End Point
The EMA-approved intermediate end points of reductions in total alcohol consumption and heavy drinking days are continuous measures and provide more statistical power to detect treatment effects than binary outcomes such as abstinence or no heavy drinking days (MacCallum et al., 2002; Yoo, 2010) . However, continuous measures may also be more difficult to translate into real-world clinical practice. In clinical practice, it is often useful to create a binary threshold to differentiate a successful outcome (i.e., normal range) from an unsuccessful outcome (i.e., abnormal range; Perlis, 2011) . The EMA-approved binary end point of reduction in WHO drinking risk levels defines a categorical reduction in WHO drinking risk level to capture a decrease in average alcohol consumption from pre treatment to an a priori defined treatment end point (e.g., the last month of treatment).
Patients who initiate treatment at the very high-risk WHO level can reduce 1, 2, or 3 levels to high risk, medium risk, or low risk, or they can become abstinent. Patients who initiate treatment at the high-risk level can reduce 1 or 2 levels to medium risk or low risk, or become abstinent. The EMA defines at least a 2-category reduction (from very high risk to medium or low risk, or from high risk to low risk) as a binary end point for alcohol clinical trials that may be useful for capturing clinically meaningful changes in consumption (Aubin et al., 2015) .
Recent work has shown that reductions in WHO drinking risk levels correspond to significant improvements in mental health and drinking consequences in a clinical sample (Witkiewitz et al., 2017a) . Similarly, in a nationally representative, population-based sample in the United States, reductions in the WHO drinking risk level were associated with significantly lower risk of developing alcohol dependence (Hasin et al., 2017) and lower risk of liver disease (Knox et al., 2018) .
Current Study
Despite recent studies, gaps remain in evaluating the utility of the WHO drinking risk level reductions. First, although population-based data show that WHO drinking risk level reductions may be associated with reduced risk of liver disease (Knox et al., 2018) , it is unclear whether WHO drinking risk level reductions are associated with improvements in more proximal measures of physical health, particularly liver enzyme levels and blood pressure, among individuals in treatment for AUD. Second, to our knowledge, no studies have examined the association between WHO drinking risk level reductions and patient-reported quality of life.
The current study examined reductions in WHO drinking risk level as a predictor of proximal indicators of physical health (blood pressure and liver enzyme levels) and selfreported quality of life. We conducted a secondary data analysis among patients who participated in a large multi site clinical trial for alcohol dependence to examine whether at least 1-and 2-level reductions in WHO drinking risk levels from pre study (i.e., baseline) to the last month of treatment were associated with improvements in systolic blood pressure (SBP) and liver enzyme levels at the end of treatment and self-reported quality of life assessed at 10 weeks following treatment. We hypothesized that at least 1-and 2-level reductions would be associated with significant improvements in physical health and self-reported quality of life.
MATERIALS AND METHODS

Participants and Procedures
Data were derived from the COMBINE study , a multi site, randomized, double-blind placebo-controlled clinical trial conducted in the United States examining combinations of medications and behavioral interventions in the treatment of alcohol dependence. To be included in COMBINE, all participants met the criteria for alcohol dependence based on the DSM-IV (American Psychiatric Association, 1994) , and reported at least 2 heavy drinking days in a consecutive 30-day period within the 90 days prior to the baseline assessment. Exclusion criteria included the presence of another substance use disorder (other than nicotine or cannabis), a psychiatric disorder requiring medication, or unstable medical conditions, including serum liver enzyme levels that were more than 3 times the upper limit of normal.
Participants for the current analyses (n = 1,226) were randomized using a 2 9 2 9 2 design in which they received (i) active naltrexone (100 mg/d) or placebo naltrexone, (ii) active acamprosate (3,000 mg/d) or placebo acamprosate, and (iii) medication management (MM) with a combined behavioral intervention (CBI) or MM alone. An additional group received the CBI intervention without MM or pills (n = 157), and this subset was excluded from the current analyses because we were most interested in examining the WHO risk reduction end points among those who received medications as part of an alcohol clinical trial.
Participants completed follow-up assessments at the end of treatment (week 16) and at 3 post treatment follow-ups: 10 weeks (week 26 after baseline), 36 weeks (week 52 after baseline), and 1 year following treatment (week 68 after baseline).
Measures
Demographics. Demographics, including age, sex, and race/ethnicity, were assessed at baseline using a self-report demographic questionnaire.
Alcohol Consumption. Daily alcohol consumption was measured using the Form-90 (Miller, 1996) and Timeline Follow-Back interview (Sobell and Sobell, 1992) . We calculated WHO drinking risk levels (see Fig. 1 ) based on participants' reports of the number of standard drinks (defined as 0.6 ounces of absolute alcohol) consumed, which were converted to grams of pure alcohol (0.6 ounces = 14 g). WHO drinking risk levels were then calculated based on the average grams of alcohol consumed per day (i.e., drinks per day). Importantly, the WHO drinking risk level is based on average grams per day, thus both drinking days and abstinent days are included to define average alcohol consumption across days over a specific time period (in the current study, we averaged over 1 month time periods). For the baseline period, we calculated the WHO drinking risk level using data from the month prior to the screening. The final end point of WHO drinking risk level during treatment was defined using the average grams of alcohol consumed per day during the last month of treatment, assessed at week 16.
For all analyses, we computed 2 binary variables that reflected at least 1-or 2-level reductions in the WHO drinking risk levels based on the reduction (i.e., "shift") from baseline to the last month of treatment. The reference group for the 1-level reduction was no change or an increase in the WHO drinking risk level from baseline to the last month of treatment, and the reference group for the 2-level reduction was the 1-level reduction, no change, or increase in the WHO risk level from baseline to the last month of treatment. This reference group was chosen to be consistent with the EMA guidelines which define a responder as achieving at least a 2-level reduction (and thus a non responder would be not achieving those reductions). Only 14 individuals had an increase in WHO risk level from baseline to the last month of treatment. As supplementary analyses, we examined at least a 2-level reduction in WHO drinking risk level with no change or an increase in WHO drinking risk level as the reference group (excluding individuals with a 1-level reduction from the reference group).
Biological Markers. SBP was assessed at each clinic visit by clinical staff. Blood samples for liver enzyme levels and liver cell pathology, including percent carbohydrate-deficient transferrin (% CDT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and c-glutamyltransferase (GGT), were collected at specified clinic visits and sent to a central laboratory (Quintiles Laboratories, Marietta, GA) which performed the GGT, AST, and ALT clinical assays utilizing automatic analyzer procedures. The Clinical Neurobiology Laboratory at the Medical University of South Carolina performed the %CDT analysis . All samples were analyzed with the same assay techniques over the course of the entire study. AST, ALT, and GGT are liver enzyme markers which typically reflect liver cell damage while % CDT is a sensitive and alcohol-specific biochemical marker of alcohol's effects on the protein transferrin. SBP and liver enzyme/ pathology levels were included as biological markers of physical health that have been shown to be associated with heavy drinking and AUD (Baros et al., 2008; LoCastro et al., 2009; Stewart et al., 2008) . SBP was examined rather than diastolic blood pressure (DBP), because prior research has shown SBP is more impacted by reductions in alcohol use than DBP (Stewart et al., 2008) and SBP is also a better predictor of cardiovascular risk (Strandberg and Pitkala, 2003) . Lower SBP and liver enzyme/ pathology levels are associated with more positive health outcomes (Kwo et al., 2017; Strandberg and Pitkala, 2003) .
Quality of Life. Quality of life was assessed with the WHO Quality of Life Brief version (WHOQOL-BREF; WHO, 1998) , the use of which was validated in the COMBINE study (Kirouac et al., 2017; LoCastro et al., 2009 ). This 25-item measure had response options ranging from 1 ("not at all") to 5 ("an extreme amount") and measured quality of life in 4 domains: physical health (e.g., "How satisfied are you with your sleep?"), psychological health ("How much do you enjoy life?"), social relationships (e.g., "How satisfied are you with your personal relationships?"), and environmental quality of life (e.g., "How satisfied are you with the conditions of your living place?"). Higher scores on each domain indicate better quality of life with maximum possible domain scores of 35 (physical health), 30 (psychological health), 15 (social health), and 40 (environmental domain). Scores in the COMBINE sample represented the full range of possible scores on each domain. The WHO-QOL-BREF was administered at baseline, 10 weeks following treatment (week 26) and 36 weeks following treatment (week 52). Internal consistency reliabilities for each domain exceeded Cronbach's a = 0.70 at all time points.
Statistical Analysis
Using multiple regression analyses, we examined biomarkers assessed at the end of treatment and quality of life assessed at 10 weeks following treatment by regressing them on the WHO 1-and 2-level reduction end points. For all regression models, we controlled for the following covariates: baseline measures of the corresponding biomarkers or WHOQOL domains, age, sex, body mass index, and smoking status, and WHO drinking risk level at baseline. All covariates were mean-centered prior to analysis. Results are reported as unstandardized regression coefficients (with standard errors), which can be interpreted as the decrease in outcomes based on achieving at least the 1-and 2-level reductions, holding all other covariates constant. The Cohen's d effect sizes, which represent the standardized mean differences between groups (e.g., no change or increases vs. at least a 1-level reduction), at the end of treatment are also reported, where d = 0.2 is a small effect, d = 0.5 is a medium effect, and d = 0.8 is a large effect (Cohen, 1992) . Potential effects of clinical research site were included as a clustering variable with standard errors adjusted using a sandwich estimator. All models were estimated in Mplus version 8 (Muth en and Muth en, 2017) with maximum-likelihood estimation to accommodate missing outcome data .
Drinking data required to calculate the WHO level reduction were missing for 84 participants (6.9% of the total sample). Attrition analyses indicated that only participant age (with younger participants having more missing data) was associated with missing data on the WHO drinking risk level variables, t(1,218) = 3.27, p < 0.001. None of the outcome measures at baseline or follow-up were associated with missing data on the WHO drinking risk level, and thus, the data were assumed to be missing at random with age included in the regression models. A set of sensitivity analyses that imputed "no change" in WHO drinking risk level when WHO level reduction data were missing (i.e., worst case scenario imputation) did not substantively change the results (available from the first author).
Sensitivity analyses were conducted to examine the effect of excluding abstainers in the WHO drinking risk level reduction analysis by examining a subgroup of participants (n = 806) that started treatment at the high-or very high-risk levels of drinking and did not achieve total abstinence during treatment. These regression analyses provided a more sensitive test of whether reductions in high-and very high-risk drinking at treatment intake to low-, medium-, or high-risk drinking (short of abstinence) at the end of treatment were associated with significant improvements in physical health and quality of life.
Similarly, we examined the effect of at least a 2-level reduction versus no change or increase in WHO risk level. These regression analyses excluded the 1-level reduction group from the comparison (i.e., reference) group, and thus, the focus is on those who achieved at least a 2-level reduction versus those who did not change or increased WHO levels. We also conducted regression analyses that included individuals who exceeded cutoffs for high levels of SBP (of 140 or above), %CDT (2.6% or above; Anton and Youngblood, 2006) , AST and ALT (35 or above; Gueorguieva et al., 2015) , and GGT (30 or above; Gueorguieva et al., 2015) at baseline.
Finally, reductions in WHO risk levels were further examined by estimating their associations with the percent of subjects who moved from above predetermined cutoffs at baseline (elevated SBP, % CDT, AST, ALT, and GGT) to below predetermined cutoffs at the end of treatment (below cutoffs on SBP, %CDT, AST, ALT, and GGT) using Pearson chi-square tests and Mantel-Haenszel odds ratios (with 95% confidence intervals).
RESULTS
Participants in this secondary analysis were mostly male (68.8%) and non-Hispanic white (76.7%) [Black/African American (7.9%), Asian (0.3%), Hispanic (11.2%), American Indian/Alaska Native (1.3%), multiracial (1.3%), and other race (1.2%)], with an average age of 44.4 years (SD = 10.2).
The number of participants categorized at each WHO drinking risk level based on drinking during the 28 days prior to screening and the last month of treatment was examined using frequency statistics. At baseline, the majority of individuals (69.1%) were in the "very high-risk" category (drinking over 101/61 [males/females] grams of pure alcohol per day on average) and there were no abstainers. During the last month of treatment (month 4), 36.3% of the sample was abstinent, 39.4% categorized as "low-risk" drinkers, 9.9% categorized as "medium-risk" drinkers, 6.3% categorized as "high-risk drinkers," and 8.1% categorized as "very highrisk" drinkers. As shown in Table 1 , abstinence and low-risk drinking were the most common WHO drinking risk levels in each month of treatment.
The binary WHO drinking risk level reduction variables were then created by calculating the reduction in drinking risk level from baseline to the last month of treatment. The majority of the sample reduced at least 1 (n = 1,011, 88.5%) or at least 2 levels (n = 881, 77.1%) from baseline to the last month of treatment. Descriptive statistics for all outcomes by risk reduction levels are provided in Table 2 .
Regression Models
Regression analyses examined the binary 1-and 2-level WHO drinking risk reductions as predictors of biomarkers at the end of treatment and quality of life at 10 weeks following treatment. As shown in Fig. 2 and Table 3 , both the 1-and 2-level reduction measures were associated with significantly lower SBP, %CDT, AST, ALT, and GGT, which indicates better functioning. The Cohen's d effect sizes can be interpreted as the standardized mean differences in outcomes based on achieving the 1-and 2-level reductions. For example, at least a 1-level reduction was associated with a 0.46 standard deviation lower SBP (p = 0.0004) and a 0.38 standard deviation lower %CDT (p = 0.006), as compared to those with no change or an increase in the WHO drinking risk level. At least a 2-level reduction was associated with a 0.27 standard deviation lower SBP (p < 0.0001) and a 0.29 standard deviation lower %CDT (p < 0.0001), as compared to those with 1-level reduction, no change, or an increase in the WHO drinking risk level. Effect size differences in AST, ALT, and GGT were in the small to medium range for both 1-and 2-level reductions and statistically significant (all p < 0.01).
Unstandardized regression coefficients, which can be interpreted as the decrease in outcomes based on achieving at least a 1-and 2-level reduction, are provided in Table 3 . For example, at least a 1-level reduction was associated with 7.99 mm Hg lower SBP (p < 0.001) and 0.70 lower %CDT (p < 0.001), indicating better functioning, as compared to those with no change or an increase in the WHO drinking risk level. At least a 2-level reduction was associated with 7.38 mm Hg lower SBP (p < 0.001) and 0.76 lower %CDT (p < 0.001), as compared to those with 1-level reduction, no change, or an increase in the WHO drinking risk level. WHO drinking risk levels were derived from patient reports of the number of standard drinks (defined as 0.6 ounces of absolute alcohol) consumed, which were converted to grams of pure alcohol (0.6 ounces = 14 g). ALT, alanine aminotransferase; AST, aspartate aminotransferase; %CDT, % carbohydrate-deficient transferrin; GGT, c-glutamyltransferase; IU/l, international units per liter; QOL, quality of life; SBP, systolic blood pressure.
Results from the regression analyses of quality-of-life outcomes are shown in Table 3 and Fig. 3 . The 1-and 2-level reduction measures were associated with significantly greater quality of life in all domains (all p < 0.001). For example, at least a 1-level reduction was associated with a 2.36 higher physical domain score, a 2.26 higher psychological domain score, and a 2.11 higher environment domain score, as compared to those with no change or an increase in the WHO drinking risk level (all p < 0.001 and Cohen's d > 0.40).
Sensitivity Analyses
Sensitivity analyses were conducted with only the subgroup of participants (n = 806) that started treatment at the high-risk or very high-risk levels and who did not achieve abstinence during treatment. In this subgroup, at least a 2-level reduction (n = 631) was associated with a statistically significant decrease in SBP, %CDT, AST, and ALT; and at least a 1-level reduction (n = 702) was associated with a statistically significant decrease in SBP (see Table S1 ). At least 1-and 2-level reductions were also associated with significantly higher quality of life across all domains (all p < 0.001).
Additionally, sensitivity analyses were conducted with only the subgroup of participants (n = 1,012) who achieved at least the 2-level reduction with no change or increase as the reference group (excluding the 1-level reduction from the reference group). As shown in Fig. 4 , the 2-level reduction was associated with significantly lower SBP (p < 0.0001), % CDT (p = 0.003), AST (p < 0.0001), ALT (p = 0.01), and GGT (p = 0.0007). The 2-level reduction was also associated with significantly higher quality of life across all domains (all p < 0.01). Importantly, at least a 1-level reduction (Fig. 2) versus no change or increase and at least a 2-level reduction (Fig. 4) Sensitivity analyses were also conducted for the subgroup of participants whose SBP (≥140 mm Hg; n = 394), %CDT (≥2.6%; n = 552), AST (≥35 IU/l; n = 385), ALT (≥35 IU/l; n = 467), and GGT (≥30 IU/l; n = 720) were elevated at baseline. Among those with elevated SBP at baseline, at least a 2-level reduction was associated with significantly lower SBP at the end of treatment (p = 0.001; see Table S2 ). The subgroup with at least a 1-level reduction did not show a significant reduction in SBP at end of treatment (p = 0.09), despite a reduction in the magnitude of SBP that was similar to that of the 2-level reduction. Among participants with elevated %CDT, AST, ALT, and GGT at baseline, the 1-and 2-level reductions were associated with significantly lower Fig. 2 . Risk level reductions from baseline to end of treatment predicting end of treatment biomarkers (N = 1,142) for 1-and 2-level reduction with 95% confidence intervals. Systolic BP, systolic blood pressure; %CDT, % carbohydrate-deficient transferrin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, c-glutamyltransferase. d = Cohen's d, which is the standardized mean effect size difference between groups (e.g., >1-level reduction vs. no change or increase) at end of treatment. p = p-value for group difference in regression models including the following covariates: baseline levels of outcome (BP or biomarker), sex, age, body mass index, smoking status, and WHO drinking risk level at baseline.
concentrations of these liver enzymes at the end of treatment (see Table S2 , all p < 0.05).
As shown in Fig. 5 , among participants with elevated % CDT, AST, ALT, and GGT at baseline, both the 1-and 2-level reductions in WHO risk were associated with significantly lower odds (all p < 0.05) of being above the cutoffs for all of these measures at the end of treatment. For % CDT, achieving at least a 1-or 2-level reduction reduced the participants' odds of remaining above the 2.6% CDT cutoff by 58% and 61%, respectively (see Table S3 ). Odds of remaining elevated on AST, ALT, and GGT were significantly decreased by more than 72% with at least a 1-or 2-level reduction (Table S3 ). For participants whose SBP was above 140 mm Hg at baseline, achieving at least a 2-level reduction significantly reduced the participants' odds of remaining above the 140 mm Hg cutoff by 54%. Sex-specific cutoffs for ALT and GGT (ALT ≥50 IU/l for males and ALT ≥35 IU/l for females; GGT ≥60 IU/l for males and GGT ≥40 IU/l for females), as well as a higher cutoff for GGT (GGT ≥100 IU/l), yielded substantively identical results (shown in Fig. 5 ).
DISCUSSION
Many people do not endorse abstinence as a goal of treatment (DeMartini et al., 2014) , and an intermediate goal of harm reduction has been proposed as a reasonable and acceptable goal in both clinical trials and treatment settings (EMA, 2010; Witkiewitz, 2013) . The current study examined whether drinking reductions, defined by achieving at least 1-or 2-level categorical reductions in the WHO (2000) drinking risk levels, were associated with significant improvements in Models include the following covariates: baseline levels of outcome (BP or biomarker), sex (male = 1), age, body mass index, smoking status (smoker = 1), and WHO drinking risk level at baseline; and adjusted for treatment site. The reference group (1-level reduction = 0) for the 1-level reduction (1-level reduction = 1) is no change or increase in WHO drinking risk level, and the reference group (2-level reduction = 0) for the 2-level reduction (2-level reduction = 1) is 1-level reduction, no change, or increase in WHO drinking risk level during any month of treatment.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; B (SE), unstandardized regression coefficient (standard error); %CDT, % carbohydrate-deficient transferrin; GGT, c-glutamyltransferase; IU/l, international units per liter; QOL, quality-of-life domains; SBP, systolic blood pressure. *p < 0.05, **p < 0.01, ***p < 0.001.
physical health and quality-of-life measures in a large, wellconducted clinical trial. Results indicated that at least 1-and 2-level reductions in the WHO drinking risk levels from baseline to the last month of treatment were associated with significantly lower SBP and lower liver enzyme levels and liver cell pathology indicating better functioning, and improved self-reported quality of life at the end of treatment. Sensitivity analyses that excluded abstainers showed that at least a 2-level reduction remained a significant predictor of lower SBP, lower %CDT, and lower AST and ALT levels, and at least 1-or 2-level reductions remained significant predictors of improvements in quality of life. Likewise, using a less conservative reference group for the 2-level reduction end point (i.e., no change or increase in WHO risk levels) resulted in even greater improvements in physical health and quality of life. In addition, those individuals with elevated SBP (≥140 mm Hg) or liver enzymes (%CDT ≥2.6%, AST ≥35, ALT ≥35, GGT ≥30, sex-specific cutoffs for ALT and GGT, and GGT ≥100) at baseline also significantly benefited from reductions in drinking. Achieving at least a 2-level reduction was associated with significantly lower SBP at the end of treatment among those with elevated blood pressure at baseline, and achieving at least 1-or 2-level reductions was each associated with significantly lower %CDT, AST, ALT, and GGT at the end of treatment among those with elevated liver enzymes and liver cell pathology at baseline. Additional analyses, not reported here, found the effects of at least 1-and 2-level reductions on physical health and quality-of-life outcomes were not impacted by medication condition or adherence to medications. Likewise, medication condition and adherence did not change the association between WHO risk level reduction and health or quality-of-life outcomes. Intermediate harm reduction targets are currently accepted by the EMA as positive end points for alcohol clinical trials. Both the FDA and EMA require that end points for alcohol clinical trials reflect meaningful clinical improvement in how patients feel or function (EMA, 2010; FDA, 2015) . The results from the current study show that 1-and 2-level WHO drinking risk reductions are associated with statistically significant and clinically meaningful improvement in measures of health and quality of life among patients with alcohol dependence enrolled in a large alcohol clinical trial. The current findings are consistent with prior work showing that reductions in drinking are associated with meaningful improvement in health and quality of life among individuals with AUD (Kline-Simon et al., 2017; Laram ee et al., 2015; LoCastro et al., 2009; Stewart et al., 2008; Witkiewitz et al., 2017b) and extend this work by indicating that 1-and 2-level WHO drinking risk reductions predict improvements. Results are also consistent with a population-based study that showed reductions in the WHO drinking risk levels to be associated with reduced risk of liver disease (Knox et al., 2018) .
The identification of valid end points that can be used to identify clinically meaningful drinking reduction in AUD treatment is important for treatment development, translation to clinical practice, and public health. Reductions in WHO drinking risk levels provide a clear threshold for clinicians to use in recommending reduced drinking goals and evaluating the effectiveness of treatment for a given patient. When compared to abstinence, reductions in drinking risk levels are also more likely to be achieved by patients. In the current analyses, the majority achieved a 1-level reduction (88.5%) or a 2-level reduction (77.1%) from baseline to the last month of treatment, whereas only a minority of patients with AUD were abstinent in the last month of treatment (36.3% in the current study). Developing treatments that specifically target drinking reduction may also be more attractive to the millions of individuals with AUD who do not seek treatment because they do not want to stop drinking (Center for Behavioral Health Statistics and Quality, 2017) .
Recent studies have shown that reductions in alcohol consumption on a broader scale could substantially reduce morbidity and mortality at the population level, positively affecting public health (Franc ßois et al., 2014; GBD 2016 Alcohol Collaborators, 2018 Laram ee et al., 2016; Rahhali et al., 2015) . It is well known that heavy alcohol consumption leads to sustained high blood pressure, which in turn predisposes to arterial disease that can lead to stroke and myocardial infarction. Liver disease is also a well-known consequence of sustained heavy alcohol use , with more than 20% of costly liver transplants being performed in individuals with alcoholic cirrhosis (Lucey, 2014) . Therefore, reductions in blood pressure and liver enzyme levels could lead to important public health benefits through reduced medical costs and improved quality of life.
The current study is not without limitations. Most importantly, we were limited to the available data in the COM-BINE study, which was designed as a clinical trial that evaluated medication response, rather than physical/psychological health per se. Thus, some of the procedures, such as blood pressure measurement, were not standardized. The % CDT assay used in this study was a second-generation assay, and there are newer, more sensitive, and specific assays currently available (Schellenberg et al., 2017) . However, both threats to the precision of measurement would be expected to bias the results against finding significant relationships by reducing effect sizes, due to greater error variance. The fact that significant relationships were observed despite measurement imprecision suggests that even greater effects may exist than were detected here. The COMBINE study also did not include assessments of quality of life during treatment and did not extend the measurement of biological markers of physical health into the months following treatment. The difference in sample sizes between groups (i.e., fewer individuals in the no change or increase reference group) is also a limitation, particularly with respect to potential violations of the assumptions of regression. Importantly, nonparametric tests of differences in outcomes by the WHO level reductions resulted in the same substantive conclusions. Also, although minimal compared to many clinical trials, some data were missing, which we accommodated using maximum-likelihood estimation. While we also conducted sensitivity analyses with alternative imputation strategies, these are, at best, estimations of how individuals with missing data were functioning at the end of treatment and/or 10 weeks following treatment. Future studies should expand the range of physical and psychological variables that might be associated with WHO drinking risk level changes and extend the analyses over longer periods of time.
The current findings add to the growing body of literature in support of the WHO drinking risk levels as an alternative to abstinence or no heavy drinking as targeted end points/ outcomes in clinical trials (Falk et al., in press; Hasin et al., 2017; Knox et al., 2018; Witkiewitz et al., 2017a) . The 1-and 2-level WHO drinking risk level reductions corresponded to significant and meaningful improvements in blood pressure and liver enzyme levels and liver cell pathology. It also appears that a change in WHO drinking risk level is sensitive to medication effects in clinical trials (Aubin et al., 2015; Falk et al., in press) . Taken together, the reduction in WHO drinking risk level is a clinically meaningful outcome that reflects meaningful reductions in alcohol consumption that could be used in clinical practice. This approach to measuring change in drinking could be more attractive to clinicians and patients than the measures currently available and could encourage greater interest in developing effective treatments for AUD. 
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